Arca
Skip to content
Tools
Tools

Epidermolysis bullosa

Drug research and approvals for epidermolysis bullosa: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 22 studies of epidermolysis bullosa are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 4 approved and 28 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 22
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 4
  • EU medicines: 2

Recruiting now

Newest posted first, of 22 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 1

Phase 2 10

Phase 1 or earlier 7

How its trials ended

130 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 36 whose ending is known, 31% met their primary endpoint, 6% missed it and 64% stopped early.

  • Completed, result not reported4535%
  • Ongoing3023%
  • Status unknown1915%
  • Met its primary endpoint118%
  • Stopped: other or unclear118%
  • Stopped: sponsor or business decision65%
  • Stopped: enrollment or feasibility43%
  • Missed its primary endpoint22%
  • Stopped: lack of efficacy22%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 21, 2024Genetically-modified epidermolysis bullosa-self-assembled skin substitute (gmeb-sass) to treat patients suffering from recessive dystrophic epidermolysis…Gmeb-sass (genetically modified epidermolysis bullosa - self assembled skin…Chu De Québec-Université LavalPending
Jan 19, 2019A double-blind, randomized, cross-over, feasibility trial of pregabalin for the treatment of recessive dystrophic epidermolysis bullosa-associated neuropathic…PregabalinThe Hospital for Sick ChildrenClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 32
Sep 12, 2025VyjuvekTreatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII…Krystal Biotech, Inc.Approved
Apr 28, 2025ZevaskynTreatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB)Abeona Therapeutics, Inc.Approved
Dec 18, 2023FilsuvezTreatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age…Chiesi Farmaceutici S.p.A.Approved
May 19, 2023VyjuvekTreatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type…Krystal Biotech, Inc.Approved
Sep 17, 2026Bioresorbable amniotic membraneTreatment of epidermolysis bullosaDiopter TechnologiesDesignated
Sep 12, 2025Sterile, processed, homogenized amniotic fluid solutionTreatment of epidermolysis bullosaEliksa Therapeutics, Inc.Designated
Jan 6, 2025Aseptic, allogeneic, pooled human umbilical cord derived…Treatment of epidermolysis bullosaINmune Bio Inc.Designated
Dec 23, 202425 C-terminal amino acids of human thrombinTreatment of epidermolysis bullosaXinnate ABDesignated
Dec 2, 2024Recombinant human type VII pro-collagenTreatment of dystrophic epidermolysis bullosaNova Anchora, LLCDesignated
Mar 28, 2024Allantoin (5-ureidohydantoin or glyoxyldiureide)Treatment of Epidermolysis BullosaParadigm TherapeuticsDesignated
May 1, 20234-Hydroxy-4'-methyoxytolanTreatment of Epidermolysis BullosaBioMendics, LLCDesignated
Jan 31, 2023Human decorin, natural anti-fibrotic protein, fused to the…Treatment of epidermolysis bullosa (EB)TheraviaDesignated
Dec 22, 2022AdenineTreatment of Epidermolysis BullosaEnergenesis Biomedical Co. Ltd.Designated
Dec 21, 2020Highly branched poly(beta-amino ester) complexed with a…Treatment of dystrophic epidermolysis bullosaAmryt Genetics LimitedDesignated
Nov 5, 2020Epidermal stem cells genetically modified with a…Treatment of Epidermolysis BullosaHolostem S.r.l.Designated

Medicines authorised in the EU

Newest first
Apr 23, 2025VyjuvekBeremagene geperpavec · orphanKrystal Biotech Netherlands B.V.EMA ↗
Jun 21, 2022FilsuvezBirch bark extract · orphanChiesi Farmaceutici S.p.AEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.